PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease
type: MedicalStudy
description: PATHFINDER: A Pragmatic, Active-comparator, Parallel-group, Randomized Trial to Evaluate the Optimal First-line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease
status: RECRUITING
study design: INTERVENTIONAL
phase: PHASE4
start date: 2023-10-25
end date: 2028-12-31
license: https://creativecommons.org/publicdomain/zero/1.0/
source: https://clinicaltrials.gov/study/NCT05928039
source organization: US National Library of Medicine
publisher: AI Analytics
sponsor: University of Calgary
study subject: Crohn Disease
keywords: PHASE4
keywords: INTERVENTIONAL
keywords: RECRUITING
keywords: Crohn Disease

AI Analytics
type: Organization